Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates
Open Access
- 26 April 2006
- journal article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 26 (17) , 4681-4689
- https://doi.org/10.1523/jneurosci.0215-06.2006
Abstract
Our recent studies show that chronic oral nicotine partially protects against striatal damage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated nonhuman primates. To identify the cellular changes associated with this protective action, we investigated the effects of nicotine treatment on stimulus-evoked dopamine release, dopamine turnover, and synaptic plasticity in striatum from lesioned and unlesioned animals. Monkeys were chronically (6 months) treated with nicotine in the drinking water and subsequently lesioned with the dopaminergic neurotoxin MPTP (6 months) while nicotine was continued. Nigrostriatal damage increased nicotinic acetylcholine receptor (nAChR)-mediated fractional dopamine release from residual terminals, primarily through changes in α3*/α6* nAChRs. In contrast, fractional receptor-evoked dopamine release was similar to control in unlesioned and lesioned animals with chronic oral nicotine. Long-term nicotine administration also attenuated the enhanced K+-evoked fractional dopamine release from synaptosomes of MPTP-lesioned animals, suggesting that nicotine treatment had a generalized effect on dopaminergic function. This premise was further supported by experiments showing that nicotine dosing decreased the elevated dopamine turnover that occurs after nigrostriatal damage. We next investigated changes in synaptic plasticity with lesioning and nicotine treatment. Nicotine treatment alone enhanced synaptic plasticity by lowering the threshold for long-term depression (LTD) in the corticostriatal pathway. MPTP lesioning led to a loss of LTD, a measure of short-term synaptic plasticity. In contrast, LTD was preserved in nicotine-treated lesioned animals. Thus, the present data show that the disruptions in striatal dopaminergic function after nigrostriatal damage were attenuated with chronic nicotine administration. These cellular alterations may underlie the ability of nicotine to maintain/restore normal function with nigrostriatal damage.Keywords
This publication has 78 references indexed in Scilit:
- Increases in α4* but not α3*/α6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatmentJournal of Neurochemistry, 2006
- Decrease in α3*/α6* Nicotinic Receptors but Not Nicotine-Evoked Dopamine Release in Monkey Brain after Nigrostriatal DamageMolecular Pharmacology, 2005
- Investigating the Receptor-independent Neuroprotective Mechanisms of Nicotine in MitochondriaJournal of Biological Chemistry, 2005
- Effects at a distance in α7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacyNeuropharmacology, 2004
- Brain-Derived Neurotrophic Factor and trkB Signaling in Parasympathetic Neurons: Relevance to Regulating α7-Containing Nicotinic Receptors and Synaptic FunctionJournal of Neuroscience, 2004
- Chemical neuroanatomy of the basal ganglia — normal and in Parkinson's diseaseJournal of Chemical Neuroanatomy, 2001
- Nicotinic Acetylcholine Receptor Agonists Promote Survival and Reduce Apoptosis of Chick Ciliary Ganglion NeuronsMolecular and Cellular Neuroscience, 2000
- Presynaptic nicotinic ACh receptorsPublished by Elsevier ,1997
- Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatumNeuroscience Letters, 1992
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991